Annual CFF
$88.52 M
-$28.71 M-24.49%
December 31, 2023
Summary
- As of February 12, 2025, XFOR annual cash flow from financing activities is $88.52 million, with the most recent change of -$28.71 million (-24.49%) on December 31, 2023.
- During the last 3 years, XFOR annual CFF has risen by +$76.12 million (+614.18%).
- XFOR annual CFF is now -37.07% below its all-time high of $140.66 million, reached on December 31, 2019.
Performance
XFOR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$20.16 M-100.00%
September 30, 2024
Summary
- As of February 12, 2025, XFOR quarterly cash flow from financing activities is $0.00, with the most recent change of -$20.16 million (-100.00%) on September 30, 2024.
- Over the past year, XFOR quarterly CFF has dropped by -$20.16 million (-100.00%).
- XFOR quarterly CFF is now -100.00% below its all-time high of $86.68 million, reached on June 30, 2019.
Performance
XFOR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$20.26 M
-$21.20 M-51.14%
September 30, 2024
Summary
- As of February 12, 2025, XFOR TTM cash flow from financing activities is $20.26 million, with the most recent change of -$21.20 million (-51.14%) on September 30, 2024.
- Over the past year, XFOR TTM CFF has dropped by -$21.20 million (-51.14%).
- XFOR TTM CFF is now -88.74% below its all-time high of $179.84 million, reached on June 30, 2023.
Performance
XFOR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XFOR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.5% | -100.0% | -51.1% |
| 3 y3 years | +614.2% | -100.0% | -51.1% |
| 5 y5 years | +1188.4% | +100.0% | -85.6% |
XFOR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -24.5% | +19.2% | -100.0% | +100.0% | -88.7% | at low |
| 5 y | 5-year | -37.1% | +614.2% | -100.0% | +100.0% | -88.7% | +63.4% |
| alltime | all time | -37.1% | +1188.4% | -100.0% | +100.0% | -88.7% | +367.2% |
X4 Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $20.26 M(-51.1%) |
| Jun 2024 | - | $20.16 M(>+9900.0%) | $41.46 M(-54.3%) |
| Mar 2024 | - | $0.00(-100.0%) | $90.64 M(+2.4%) |
| Dec 2023 | $88.52 M(-24.5%) | $97.00 K(-99.5%) | $88.52 M(-40.6%) |
| Sep 2023 | - | $21.20 M(-69.4%) | $149.06 M(-17.1%) |
| Jun 2023 | - | $69.34 M(-3364.5%) | $179.84 M(+63.3%) |
| Mar 2023 | - | -$2.12 M(-103.5%) | $110.15 M(-6.0%) |
| Dec 2022 | $117.23 M(+57.9%) | $60.64 M(+16.7%) | $117.23 M(+44.5%) |
| Sep 2022 | - | $51.98 M(<-9900.0%) | $81.16 M(+228.1%) |
| Jun 2022 | - | -$347.00 K(-107.0%) | $24.74 M(+2.4%) |
| Mar 2022 | - | $4.96 M(-79.8%) | $24.16 M(-67.5%) |
| Dec 2021 | $74.25 M(+499.0%) | $24.57 M(-653.1%) | $74.25 M(+29.6%) |
| Sep 2021 | - | -$4.44 M(+380.7%) | $57.30 M(-6.8%) |
| Jun 2021 | - | -$924.00 K(-101.7%) | $61.46 M(-1.6%) |
| Mar 2021 | - | $55.04 M(+621.5%) | $62.45 M(+403.9%) |
| Dec 2020 | $12.39 M | $7.63 M(-2786.3%) | $12.39 M(-80.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$284.00 K(-536.9%) | $65.05 M(+10.4%) |
| Jun 2020 | - | $65.00 K(-98.7%) | $58.92 M(-59.5%) |
| Mar 2020 | - | $4.98 M(-91.7%) | $145.53 M(+3.5%) |
| Dec 2019 | $140.66 M(+1947.5%) | $60.28 M(-1039.9%) | $140.66 M(+58.2%) |
| Sep 2019 | - | -$6.41 M(-107.4%) | $88.89 M(-6.2%) |
| Jun 2019 | - | $86.68 M(>+9900.0%) | $94.72 M(+1144.8%) |
| Mar 2019 | - | $113.00 K(-98.7%) | $7.61 M(+10.8%) |
| Dec 2018 | $6.87 M(-93.2%) | $8.51 M(-1559.9%) | $6.87 M(-87.9%) |
| Sep 2018 | - | -$583.00 K(+35.0%) | $56.71 M(-6.9%) |
| Jun 2018 | - | -$432.00 K(-31.0%) | $60.93 M(-36.7%) |
| Mar 2018 | - | -$626.00 K(-101.1%) | $96.30 M(-4.9%) |
| Dec 2017 | $101.26 M(+458.0%) | $58.35 M(+1503.4%) | $101.26 M(+136.0%) |
| Sep 2017 | - | $3.64 M(-89.6%) | $42.91 M(+9.3%) |
| Jun 2017 | - | $34.94 M(+705.8%) | $39.27 M(+805.8%) |
| Mar 2017 | - | $4.34 M | $4.34 M |
| Dec 2016 | $18.15 M(+57.7%) | - | - |
| Dec 2015 | $11.51 M | - | - |
FAQ
- What is X4 Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals annual CFF year-on-year change?
- What is X4 Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals quarterly CFF year-on-year change?
- What is X4 Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals TTM CFF year-on-year change?
What is X4 Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of XFOR is $88.52 M
What is the all time high annual CFF for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high annual cash flow from financing activities is $140.66 M
What is X4 Pharmaceuticals annual CFF year-on-year change?
Over the past year, XFOR annual cash flow from financing activities has changed by -$28.71 M (-24.49%)
What is X4 Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of XFOR is $0.00
What is the all time high quarterly CFF for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high quarterly cash flow from financing activities is $86.68 M
What is X4 Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, XFOR quarterly cash flow from financing activities has changed by -$20.16 M (-100.00%)
What is X4 Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of XFOR is $20.26 M
What is the all time high TTM CFF for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high TTM cash flow from financing activities is $179.84 M
What is X4 Pharmaceuticals TTM CFF year-on-year change?
Over the past year, XFOR TTM cash flow from financing activities has changed by -$21.20 M (-51.14%)